New Clinical and Real-World Data Support Use of DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
Retrieved on:
Saturday, December 11, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Dexamethasone, MRD, Clinical trial, Lymphatic system, ASH, Patient, Abstract, Lenalidomide, Physician, EMEA, Janssen Pharmaceuticals, VRD, Minimal, Multiple myeloma, Bortezomib, Highlight, SCR, Society, Johnson & Johnson, Pharmaceutical industry, the GRIFFIN Study1,6, the MAIA Study7, daratumumab, Multiple Myeloma, the Janssen Pharmaceutical Companies of Johnson & Johnson, THE GRIFFIN STUDY1,6, THE MAIA STUDY7, DARATUMUMAB, MULTIPLE MYELOMA, THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
The clinical data presented at ASH support daratumumab as a foundational therapy for patients with newly diagnosed multiple myeloma in transplant-ineligible populations, said Imran Khan, M.D., Ph.D., U.S. Vice President, Medical Affairs, Hematology, Janssen Scientific Affairs, LLC.
Key Points:
- The clinical data presented at ASH support daratumumab as a foundational therapy for patients with newly diagnosed multiple myeloma in transplant-ineligible populations, said Imran Khan, M.D., Ph.D., U.S. Vice President, Medical Affairs, Hematology, Janssen Scientific Affairs, LLC.
- Real-world evidence about efficacy, safety and adherence is becoming increasingly important for clinicians in optimising treatment approaches for patients with multiple myeloma.
- Janssen is committed to exploring the potential of daratumumab for patients with multiple myeloma across the spectrum of the disease.
- Real-World Patient Characteristics and Treatment Outcomes Among Newly Diagnosed Multiple Myeloma Patients Initiating Daratumumab, Lenalidomide, and Dexamethasone As First-Line Therapy.